{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T13:09:06Z","timestamp":1771679346663,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ctarc.2022.100672","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T02:14:31Z","timestamp":1670811271000},"page":"100672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Evaluation of HE4 as a prognostic biomarker in uterine cervical cancer,"],"prefix":"10.1016","volume":"34","author":[{"given":"Harshita","family":"Dubey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1123-338X","authenticated-orcid":false,"given":"Amar","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julieana","family":"Durai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Lakshmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swati","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Meena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.D.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranay","family":"Tanwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanat","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctarc.2022.100672_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin"},{"key":"10.1016\/j.ctarc.2022.100672_bib0002","unstructured":"Three year report of PBCR 2012-2014 [Internet]. [cited 2021 Aug 2]. Available from: https:\/\/www.ncdirindia.org\/NCRP\/ALL_NCRP_REPORTS\/PBCR_REPORT_2012_2014\/index.htm."},{"key":"10.1016\/j.ctarc.2022.100672_bib0003","unstructured":"Predicting the future burden of cancer | Nat. Rev. Cancer [Internet]. [cited 2021 Aug 2]. Available from: https:\/\/www.nature.com\/articles\/nrc1781."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100672_bib0004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J. Pathol"},{"issue":"11","key":"10.1016\/j.ctarc.2022.100672_bib0005","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jnci\/87.11.779","article-title":"Cancer causes revisited: human Papillomavirus and cervical neoplasia","volume":"87","author":"Franco","year":"1995","journal-title":"JNCI J. Natl. Cancer Inst"},{"issue":"17","key":"10.1016\/j.ctarc.2022.100672_bib0006","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/sj.onc.1205363","article-title":"The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms","volume":"21","author":"Bingle","year":"2002","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.ctarc.2022.100672_bib0007","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1095\/biolreprod45.2.350","article-title":"A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors1","volume":"45","author":"Kirchhoff","year":"1991","journal-title":"Biol. Reprod"},{"issue":"13","key":"10.1016\/j.ctarc.2022.100672_bib0008","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstr\u00f6m","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctarc.2022.100672_bib0009","unstructured":"Comprehensive analysis of HE4 expression in normal and malignant human tissues | Mod. Pathol. [Internet]. [cited 2021 Aug 2]. Available from: https:\/\/www.nature.com\/articles\/3800612."},{"key":"10.1016\/j.ctarc.2022.100672_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/468615","article-title":"GRP78 protein expression in ovarian cancer patients and perspectives for a drug-targeting approach","volume":"2012","author":"Delie","year":"2012","journal-title":"J. Oncol"},{"issue":"29","key":"10.1016\/j.ctarc.2022.100672_bib0011","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1016\/S0021-9258(17)32244-5","article-title":"Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland","volume":"269","author":"Yu","year":"1994","journal-title":"J. Biol. Chem"},{"issue":"7","key":"10.1016\/j.ctarc.2022.100672_bib0012","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1590\/S1807-59322009000700006","article-title":"Prostasin, a potential tumor marker in ovarian cancer\u2013a pilot study","volume":"64","author":"Costa","year":"2009","journal-title":"Clin. Sao Paulo Braz"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100672_bib0013","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13048-016-0228-9","article-title":"The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer","volume":"9","author":"Tamir","year":"2016","journal-title":"J. Ovarian Res"},{"key":"10.1016\/j.ctarc.2022.100672_bib0014","series-title":"Clinical Methods: The History, Physical, and Laboratory Examinations","article-title":"Pap Test","author":"Naib","year":"1990"},{"key":"10.1016\/j.ctarc.2022.100672_bib0015","article-title":"The value and clinical significance of tumor marker detection in cervical cancer","volume":"2021","author":"Sun","year":"2021","journal-title":"Sci. Program"},{"key":"10.1016\/j.ctarc.2022.100672_bib0016","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1186\/s12885-018-5007-0","article-title":"Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates","volume":"18","author":"Couvreur","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2022.100672_bib0017","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/labmed\/lmx080","article-title":"Cervical cancer markers: epigenetics and microRNAs","volume":"49","author":"Laengsri","year":"2018","journal-title":"Lab. Med"},{"key":"10.1016\/j.ctarc.2022.100672_bib0018","first-page":"215","article-title":"Biomarkers in Cervical Cancer","volume":"1","author":"Yim","year":"2007","journal-title":"Biomark. Insights"},{"key":"10.1016\/j.ctarc.2022.100672_bib0019","unstructured":"Cervical cancer - risk factors [Internet]. Cancer.Net. 2012 [cited 2021 Nov 10]. Available from: https:\/\/www.cancer.net\/cancer-types\/cervical-cancer\/risk-factors."},{"issue":"2","key":"10.1016\/j.ctarc.2022.100672_bib0020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1056\/NEJMcp0901926","article-title":"Clinical practice. Screening for ovarian cancer","volume":"361","author":"Clarke-Pearson","year":"2009","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.ctarc.2022.100672_bib0021","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ajog.2008.04.009","article-title":"The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?","volume":"199","author":"Nossov","year":"2008","journal-title":"Am. J. Obstet. Gynecol"},{"issue":"4","key":"10.1016\/j.ctarc.2022.100672_bib0022","article-title":"CA 125: the past and the future","volume":"13","author":"Rc","year":"1998","journal-title":"Int. J. Biol. Mark."},{"issue":"6884","key":"10.1016\/j.ctarc.2022.100672_bib0023","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/bmj.306.6884.1030","article-title":"Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography","volume":"306","author":"Jacobs","year":"1993","journal-title":"BMJ"},{"key":"10.1016\/j.ctarc.2022.100672_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.584022","article-title":"Pre-treatment serum HE4 level as a novel independent prognostic biomarker for uterine cervical carcinoma patients","author":"Bignotti","year":"2020","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2022.100672_bib0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijgo.2015.07.024","article-title":"Systematic reviews and meta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy","volume":"132","author":"Mustafa","year":"2016","journal-title":"Int. J. Gynecol. Obstet"},{"issue":"6","key":"10.1016\/j.ctarc.2022.100672_bib0026","first-page":"548","article-title":"The emerging role of HE4 in the evaluation of advanced epithelial ovarian and endometrial carcinomas","volume":"27","author":"Simmons","year":"2013","journal-title":"Oncol. Williston Park N"},{"key":"10.1016\/j.ctarc.2022.100672_bib0027","unstructured":"Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients | Br. J. Cancer [Internet]. [cited 2021 Aug 3]. Available from: https:\/\/www.nature.com\/articles\/bjc2011109."},{"key":"10.1016\/j.ctarc.2022.100672_bib0028","article-title":"Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management","year":"2021","journal-title":"Cancer Epidemiol., Biomark. Prevent."},{"issue":"12","key":"10.1016\/j.ctarc.2022.100672_bib0029","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1515\/cclm-2011-0757","article-title":"Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome","volume":"50","author":"Zanotti","year":"2012","journal-title":"Clin. Chem. Lab. Med"},{"key":"10.1016\/j.ctarc.2022.100672_bib0030","article-title":"Serum human epididymis protein 4 as a prognostic marker in cervical cancer","volume":"29","author":"Hwang","year":"2022","journal-title":"Cancer Control J. Moffitt Cancer Cent"},{"issue":"5","key":"10.1016\/j.ctarc.2022.100672_bib0031","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcla.20340","article-title":"The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass","volume":"23","author":"Montagnana","year":"2009","journal-title":"J. Clin. Lab. Anal"},{"issue":"2","key":"10.1016\/j.ctarc.2022.100672_bib0032","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5603\/GP.a2017.0011","article-title":"Tissue expression of human epididymal secretory protein 4 may be useful in the differential diagnosis of uterine cervical tumors","volume":"88","author":"Diniz","year":"2017","journal-title":"Ginekol. Pol"},{"issue":"4","key":"10.1016\/j.ctarc.2022.100672_bib0033","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s13277-012-0356-9","article-title":"Serum HE4 as a diagnostic and prognostic marker for lung cancer","volume":"33","author":"Iwahori","year":"2012","journal-title":"Tumor Biol"},{"issue":"39","key":"10.1016\/j.ctarc.2022.100672_bib0034","doi-asserted-by":"crossref","first-page":"e17198","DOI":"10.1097\/MD.0000000000017198","article-title":"HE4 as a biomarker for diagnosis of lung cancer","volume":"98","author":"He","year":"2019","journal-title":"Medicine (Baltimore)"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222001630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222001630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:34:48Z","timestamp":1762842888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294222001630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":34,"alternative-id":["S2468294222001630"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100672","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of HE4 as a prognostic biomarker in uterine cervical cancer,","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100672","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100672"}}